52 results on '"Loberiza, Fausto R."'
Search Results
2. Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation
3. Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial
4. Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
5. Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades
6. Review of Antibody-Based Immunotherapy in the Treatment of Non-Hodgkin Lymphoma and Patterns of Use
7. Phase I/II Study of Bortezomib-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma
8. Association Between Race and Survival of Patients With Non–Small-Cell Lung Cancer in the United States Veterans Affairs Population
9. Impact of Conditioning Regimen on Outcome of 2-Year Disease-Free Survivors of Autologous Stem Cell Transplantation for Hodgkin Lymphoma
10. Does Functional Imaging Distinguish Nodular Lymphocyte-Predominant Hodgkin Lymphoma From T-Cell/Histiocyte-Rich Large B-Cell Lymphoma?
11. Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma
12. Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence
13. Methodological and Logistical Considerations to Study Design and Data Collection in Racial/Ethnic Minority Populations Evaluating Outcome Disparity in Hematopoietic Cell Transplantation
14. Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)
15. Variation in Supportive Care Practices in Hematopoietic Cell Transplantation
16. Long-Term Outcomes of Autologous Stem Cell Transplantation for Follicular Non-Hodgkin Lymphoma: Effect of Histological Grade and Follicular International Prognostic Index
17. Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence
18. Impact of Donor and Recipient Sex and Parity on Outcomes of HLA-Identical Sibling Allogeneic Hematopoietic Stem Cell Transplantation
19. Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation
20. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States
21. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
22. Differences in Characteristics of US Hematopoietic Stem Cell Transplantation Centers by Proportion of Racial or Ethnic Minorities
23. ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited
24. Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients
25. What is quality in a transplant program?
26. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry
27. Autologous transplantation for diffuse aggressive Non-Hodgkin lymphoma in first relapse or second remission
28. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
29. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma
30. Optimistic expectations and survival after hematopoietic stem cell transplantation
31. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling
32. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase
33. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion
34. Practice Mapping in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia (RR ALL): The Use of Measurable Residual Disease (MRD) Assessment in Real-World U.S. Community Oncology Practice
35. 44 - Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin for Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)
36. 435 - Veno-Occlusive Disease Characteristics in Pediatric Patients with Acute Myeloid Leukemia Receiving Gemtuzumab Ozogamicin before Allogeneic Stem Cell Transplant
37. 434 - Characterization of Veno-Occlusive Disease (VOD) in Adult Patients (Pts) with Acute Myeloid Leukemia (AML) Receiving Gemtuzumab Ozogamicin (GO) before Allogeneic Stem Cell Transplant (SCT)
38. Clinicopathologic Features, Management and Outcomes of Blastoid Variant (BV) of Mantle Cell Lymphoma (MCL): A Nebraska Lymphoma Study Group (NLSG) Experience
39. Lack Of Clinical Benefit For Routine Surveillance Imaging For Diffuse Large B-Cell Lymphoma In First Complete Remission
40. A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial
41. Lymphoma with Features Intermediate Between DLBCL and Burkitt Lymphoma: Better Outcome with Intensive Chemotherapy Regimens
42. A Retrospective Analysis Comparing BEAM Versus Melphalan Prior to First Autologous Peripheral Blood Hematopoietic Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Patients
43. What Predicts Agreement about Prognosis Between Patients and Physicians?
44. Trend Analysis of 5-Year All-Cause Mortality After Autologous Stem Cell Transplantation in Patients with Lymphoma and Multiple Myeloma
45. Psychological Correlates of Having Advance Care Planning in Patients with Hematological Malignancies.
46. Content of Hematologic Malignancies Consultations: Good and Bad News From the HEMA-COMM Study.
47. Survival Disparities in Patients with Lymphoma According to Place of Residence and Treatment Provider: A Population-Based Study
48. The Impact of Histological Subtypes on Outcome in Patients with Mantle Cell Lymphoma Treated with or without Autologous Stem Cell Transplant.
49. Factors Affecting the Development of Atrial Fibrillation and Atrial Flutter (AF) Following Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT).
50. Prevalence of Microbially Contaminated Hematopoietic Stem Cell Products.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.